Osteonecrosis of the maxilla in a patient with a history of bisphosphonate therapy

Journal of the Canadian Dental Association

Volumn 71, Issue 2, 2005, Pages

  Melo, Maico D ^a   Obeid, George ^a  

^a WASHINGTON HOSPITAL CENTER   (United States)

Author keywords

Case report; Diphosphonates adverse effects; Osteonecrosis chemically induced

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE; ZOLEDRONIC ACID;

AGED; BONE NECROSIS; CHEMICALLY INDUCED DISORDER; DEBRIDEMENT; FEMALE; HUMAN; JAW DISEASE; REVIEW; TOOTH EXTRACTION;

AGED; BONE DENSITY CONSERVATION AGENTS; DEBRIDEMENT; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; MAXILLARY DISEASES; OSTEONECROSIS; TOOTH EXTRACTION;

EID: 18944388211     PISSN: 14882159     EISSN: 14882159     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Aparicio A, Gardner A, Tu Y, Savage A, Berenson J, Lichtenstein A, and others. In vitro cytoreductive effects on multiple myeloma cell induced by bisphosphonates. Leukemia 1998; 12(2):220-9.
2. Lee MV, Fong EM, Singer FR, Guenette RS. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 2001; 61(6):2602-8.
3. Riebeling C, Forsea AM, Raisova M, Orfanos CE, Geilen CC. The bisphosphonate pamidronate induces apoptosis in human melanoma cells in vitro. Br J Cancer 2002; 87(3):366-71.
4. Shipman CM, Rogers MJ, Apperley JF, Russell RG, Croucher PI. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumor activity. Br J Haematol 1997; 98(3):665-72.
5. Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000; 82(8):1459-68.
6. Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, and others. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Phamacol Exp Ther 2002; 302(3):1055-61.
7. Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, and others. Bisphosphonates inhibit angiogenesis in vitro and testosterone- stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002; 62(22):6538-44.
8. Berenson JR. Advances in the biology and treatment of myeloma bone disease. Semin Oncol 2002; 29(6 Suppl 17):11-6.
9. Powles T, Paterson S, Kanis JA, McCloskey E, Ashley S, Tidy A, and others. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002; 20(15):3219-24.
10. Saad F, Gleason DM, Murray R, Tchekmedyian S, Veneer P, Lacombe L, and others. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94(19):1458-68.
11. Marx RE. Pamidronate (Aredia) and zoldronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral and Maxillofac Surg 2003; 61(9):1115-7.
12. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral and Maxillofac Surg 2004; 62(5):527-34.
13. Fleisch H. Development of bisphosphonates. Breast Cancer Res 2002; 4(1):30-4.
14. Russell RG, Rogers MJ, Frith JC, Luckman SP, Coxen FP, Benford HL, and others. The pharmacology of bisphosphonates and new insights into their mechanisms of action. J Bone Miner Res 1999; Suppl 2:53-65.
15. Lin JH, Russell RG, Gertz B. Pharmacokinetics of alendronate: an overview. Int J Clin Pract 1999; 101:18-26.
16. Starck WJ, Epker BN. Failure of osseointegrated dental implants after diphosphonate therapy for osteoporosis: a case report. Int J Oral Maxillofac Implants 1995; 10(1):74-8.
17. Teronen O, Konttinen YT, Lindqvist C, Salo T, Ingman T, Lauhio A, and others. Human neutrophil collagenase MMP-8 in peri-implant sulcus fluid and its inhibition by clodronate. J Dent Res 1997; 76(9):1529-37.
18. Marx, RE: Osteoradionecrosis: a new concept of its pathophysiology. J Oral Maxillofac Surg 1983; 41(5):283-8.